803 related articles for article (PubMed ID: 15479682)
1. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
Kruis W; Fric P; Pokrotnieks J; Lukás M; Fixa B; Kascák M; Kamm MA; Weismueller J; Beglinger C; Stolte M; Wolff C; Schulze J
Gut; 2004 Nov; 53(11):1617-23. PubMed ID: 15479682
[TBL] [Abstract][Full Text] [Related]
2. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
Adam B; Liebregts T; Holtmann G
Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
[No Abstract] [Full Text] [Related]
3. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
[TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
Kruis W; Schütz E; Fric P; Fixa B; Judmaier G; Stolte M
Aliment Pharmacol Ther; 1997 Oct; 11(5):853-8. PubMed ID: 9354192
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study.
Langhorst J; Varnhagen I; Schneider SB; Albrecht U; Rueffer A; Stange R; Michalsen A; Dobos GJ
Aliment Pharmacol Ther; 2013 Sep; 38(5):490-500. PubMed ID: 23826890
[TBL] [Abstract][Full Text] [Related]
6. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
Scaldaferri F; Gerardi V; Mangiola F; Lopetuso LR; Pizzoferrato M; Petito V; Papa A; Stojanovic J; Poscia A; Cammarota G; Gasbarrini A
World J Gastroenterol; 2016 Jun; 22(24):5505-11. PubMed ID: 27350728
[TBL] [Abstract][Full Text] [Related]
7. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
[TBL] [Abstract][Full Text] [Related]
8. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
[TBL] [Abstract][Full Text] [Related]
9. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
Henker J; Müller S; Laass MW; Schreiner A; Schulze J
Z Gastroenterol; 2008 Sep; 46(9):874-5. PubMed ID: 18810672
[TBL] [Abstract][Full Text] [Related]
10. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Zocco MA; dal Verme LZ; Cremonini F; Piscaglia AC; Nista EC; Candelli M; Novi M; Rigante D; Cazzato IA; Ojetti V; Armuzzi A; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2006 Jun; 23(11):1567-74. PubMed ID: 16696804
[TBL] [Abstract][Full Text] [Related]
12. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
[TBL] [Abstract][Full Text] [Related]
13. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis.
Losurdo G; Iannone A; Contaldo A; Ierardi E; Di Leo A; Principi M
J Gastrointestin Liver Dis; 2015 Dec; 24(4):499-505. PubMed ID: 26697577
[TBL] [Abstract][Full Text] [Related]
14. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.
Watanabe M; Hanai H; Nishino H; Yokoyama T; Terada T; Suzuki Y
Inflamm Bowel Dis; 2013 Jul; 19(8):1681-90. PubMed ID: 23624890
[TBL] [Abstract][Full Text] [Related]
15. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
16. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Pica R; Cassieri C; Cocco A; Zippi M; Marcheggiano A; De Nitto D; Avallone EV; Crispino P; Occhigrossi G; Paoluzi P
Dig Liver Dis; 2015 Nov; 47(11):933-7. PubMed ID: 26391602
[TBL] [Abstract][Full Text] [Related]
18. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
19. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
20. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
